CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients

被引：0
|
作者：
M. V. Lima
G. S. Ribeiro
E. T. Mesquita
P. R. Victer
R. Vianna-Jorge
机构：
[1] Hospital Universitário Antônio Pedro,Departamento de Medicina Clínica
[2] Universidade Federal Fluminense,Departamento de Patologia
[3] Hospital Universitário Antônio Pedro,Departamento de Farmacologia Básica e Clínica
[4] Universidade Federal Fluminense,Coordenação de Pesquisa
[5] Universidade Federal do Rio de Janeiro,undefined
[6] Cidade Universitária,undefined
[7] Centro de Ciências da Saúde,undefined
[8] Instituto Nacional de Câncer,undefined
来源：
European Journal of Clinical Pharmacology | 2008年 / 64卷
关键词：
Gene polymorphism; Brazilians; Warfarin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：9 / 15
页数：6
相关论文
共 50 条
  • [1] CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients
    Lima, M. V.
    Ribeiro, G. S.
    Mesquita, E. T.
    Victer, P. R.
    Vianna-Jorge, R.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (01) : 9 - 15
  • [2] Clinical value of allele variants of cytochrome CYP2C9 gene for anticoagulation therapy with warfarin
    Sirotkina, O
    Ulitina, AS
    Taraskina, AE
    Kadinskaya, MI
    Vavilova, TV
    Pchelina, SN
    Schwarts, EI
    KARDIOLOGIYA, 2005, 45 (04) : 61 - 63
  • [3] Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy
    Furuya, H
    FernandezSalguero, P
    Gregory, W
    Taber, H
    Steward, A
    Gonzalez, FJ
    Idle, JR
    PHARMACOGENETICS, 1995, 5 (06): : 389 - 392
  • [4] Association of Cyp2c9 gene polymorphism with bleeding as a complication of warfarin therapy
    Samardzija, Marina
    Topic, Elizabeta
    Stefanovic, Mario
    Zibar, Lada
    Samardzija, Goran
    Balen, Sanja
    Vcev, Aleksandar
    Domanovic, Dragoslav
    Mirat, Jure
    Barbic, Jerko
    COLLEGIUM ANTROPOLOGICUM, 2008, 32 (02) : 557 - 564
  • [5] CYP2C9 genetic polymorphisms and warfarin
    Redman, AR
    Dickmann, LJ
    Kidd, RS
    Goldstein, JA
    Ritchie, DM
    Hon, YY
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2004, 10 (02) : 149 - 154
  • [6] Analysis of CYP2C9 polymorphisms (*2 and*3) in warfarin therapy patients in Pakistan. Association of CYP2C9 polymorphisms (*2 and*3) with warfarin dose, age, PT and INR
    Yasmeen, Faiza
    Ghafoor, Muhammad Bilal
    Khalid, Abdul Wadood
    Latif, Waqas
    Mohsin, Shahida
    Khaliq, Shagufta
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2015, 40 (02) : 218 - 224
  • [7] Warfarin therapy in a patient homozygous for the CYP2C9*3 allele
    Ablin, J
    Cabili, S
    Lagziel, A
    Peretz, H
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2002, 4 (02): : 139 - 141
  • [8] Analysis of CYP2C9 polymorphisms (*2 and *3) in warfarin therapy patients in Pakistan. Association of CYP2C9 polymorphisms (*2 and*3) with warfarin dose, age, PT and INR
    Faiza Yasmeen
    Muhammad Bilal Ghafoor
    Abdul Wadood Khalid
    Waqas Latif
    Shahida Mohsin
    Shagufta Khaliq
    Journal of Thrombosis and Thrombolysis, 2015, 40 : 218 - 224
  • [9] The effect of CYP2C9*2, CYP2C9*3, and VKORC1-1639 G > A polymorphism in patients under warfarin therapy in city of Kermanshah
    Hosseinkhani, Zohreh
    Sadeghalvad, Mona
    Norooznezhad, Fathemeh
    Khodarahmi, Reza
    Fazilati, Mohammad
    Mahnam, Azadeh
    Fattahi, Ali
    Mansouri, Kamran
    RESEARCH IN PHARMACEUTICAL SCIENCES, 2018, 13 (04) : 377 - 384
  • [10] Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer
    Ruud, Ellen
    Holmstrom, Henrik
    Bergan, Stein
    Wesenberg, Finn
    PEDIATRIC BLOOD & CANCER, 2008, 50 (03) : 710 - 713
12345